Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients

References

1. 1.↵
   World Health Organization. COVID-19 Dashboard. [Updated 2021; cited 2021 September 6]. Available from: https://covid19.who.int/

   Google Scholar
2. 2.↵
   1. Porfidia A,
   2. Valeriani E,
   3. Pola R,
   4. Porreca E,
   5. Rutjes A,
   6. Di Nisio M.

   Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thrombosis Research 2020; 196: 67–74.

   OpenUrlCrossRefPubMedGoogle Scholar
3. 3.↵
   1. Motta J,
   2. Ogunnaike R,
   3. Shah R,
   4. Stroever S,
   5. Cedeño H,
   6. Thapa S, et al.

   Clinical outcomes with the use of prophylactic versus therapeutic anticoagulation in coronavirus disease 2019. Crit Care Explor 2020; 2: e0309.

   OpenUrlPubMedGoogle Scholar
4. 4.↵
   1. Loo J,
   2. Spittle D,
   3. Newnham M.

   COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021; 76: 412–420.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
5. 5.↵
   1. Iba T,
   2. Levy J,
   3. Levi M,
   4. Thachil J.

   Coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 2103–2109.

   OpenUrlPubMedGoogle Scholar
6. 6.↵
   1. Musoke N,
   2. Lo K,
   3. Albano J,
   4. Peterson E,
   5. Bhargav R,
   6. Gul F, et al.

   Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020; 196: 227–230.

   OpenUrlCrossRefPubMedGoogle Scholar
7. 7.
   1. Tang N,
   2. Bai H,
   3. Chen X,
   4. Gong J,
   5. Li D,
   6. Sun Z.

   Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Thromb Res 2020; 18: 1094–1099.

   OpenUrlGoogle Scholar
8. 8.↵
   1. Ionescu F,
   2. Grasso-Knight G,
   3. Castillo E,
   4. Naeem E,
   5. Petrescu I,
   6. Imam Z, et al.

   Therapeutic anticoagulation delays death in COVID-19 patients: Cross-sectional analysis of a prospective cohort. TH Open 2020; 4: e263–e270.

   OpenUrlGoogle Scholar
9. 9.↵
   1. Lu YF,
   2. Pan LY,
   3. Zhang WW,
   4. Cheng F,
   5. Hu SS,
   6. Zhang X, et al.

   A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis 2020; 100: 34–41.

   OpenUrlCrossRefGoogle Scholar
10. 10.↵
    1. Begbie M,
    2. Notley C,
    3. Tinlin S,
    4. Sawyer L,
    5. Lillicrap D

    (2000) The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 84: 216–222.

    OpenUrlPubMedGoogle Scholar
11. 11.↵
    1. SJ Zost,
    2. Gilchuk P,
    3. Case JB,
    4. Binshtein E,
    5. Chen RE,
    6. Nkolola JP, et al.

    Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 2020; 584: 443–449.

    OpenUrlGoogle Scholar
12. 12.↵
    1. Han H,
    2. Ma Q,
    3. Li C,
    4. Liu R,
    5. Zhao L,
    6. Wang W,
    7. Zhang P, et al.

    Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020; 9: 1123–1130.

    OpenUrlGoogle Scholar
13. 13.
    1. McGonagle D,
    2. Sharif K,
    3. O’Regan A,
    4. Bridgewood C.

    The Role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19: 102537.

    OpenUrlCrossRefPubMedGoogle Scholar
14. 14.↵
    1. Wan S,
    2. Yi Q,
    3. Fan S,
    4. LV J,
    5. Zhang X,
    6. Guo L, et al.

    Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 189: 428–437.

    OpenUrlCrossRefGoogle Scholar
15. 15.↵
    1. de Jonge E,
    2. Friederich PW,
    3. Vlasuk GP,
    4. Rote WE,
    5. Vroom MB,
    6. Levi M, et al.

    Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003; 10: 495–497.

    OpenUrlCrossRefPubMedGoogle Scholar
16. 16.↵
    1. Mutlu GM,
    2. Green D,
    3. Bellmeyer A,
    4. Baker CM,
    5. Burgess Z,
    6. Rajamannan N, et al.

    Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest 2007; 117: 2952–2961.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
17. 17.↵
    1. Tomaske M,
    2. Candinas R,
    3. Weiss M,
    4. Bauersfeld U.

    Safety and efficacy of pediatric outpatient radio frequency catheter ablations. Int J Cardiol 2011; 148: 276–279

    OpenUrlPubMedGoogle Scholar
18. 18.↵
    1. Schmitt FCF,
    2. Manolov V,
    3. Morgenstern J,
    4. Fleming T,
    5. Heitmeier S,
    6. Uhle F, et al.

    Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9: 19.

    OpenUrlGoogle Scholar
19. 19.↵
    1. Di Minno A,
    2. Ambrosino P,
    3. Calcaterra I,
    4. Di Minno MND.

    COVID-19 and Venous thromboembolism: A meta-analysis of literature studies. Semin Thromb Hemost 2020; 46: 763–771.

    OpenUrlCrossRefPubMedGoogle Scholar
20. 20.↵
    1. Al-Samkari H,
    2. Karp Leaf RS,
    3. Dzik WH,
    4. Carlson JCT,
    5. Fogerty AE,
    6. Waheed A, et al.

    COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136: 489–500.

    OpenUrlCrossRefPubMedGoogle Scholar
21. 21.↵
    1. Mai V,
    2. Tan BK,
    3. Mainbourg S,
    4. Potus F,
    5. Cucherat M,
    6. Lega JC, et al.

    Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascul Pharmacol 2021; 139: 106882.

    OpenUrlCrossRefPubMedGoogle Scholar
22. 22.↵
    1. Lawler PR,
    2. Goligher EC,
    3. Berger JS, et al.

    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med 2021; 385: 790–802.

    OpenUrlCrossRefPubMedGoogle Scholar
23. 23.↵
    1. Goligher EC,
    2. Bradbury CA,
    3. McVerry BJ, et al.

    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med 2021; 385: 777–789.

    OpenUrlCrossRefPubMedGoogle Scholar
24. 24.↵
    1. Klok FA,
    2. Kruip MJHA,
    3. van der Meer NJM,
    4. Arbous MS,
    5. Gommers DAMPJ,
    6. Kant KM, et al.

    Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147.

    OpenUrlCrossRefPubMedGoogle Scholar
25. 25.↵
    1. Russo V,
    2. Di Maio M,
    3. Attena E,
    4. Silverio A,
    5. Scudiero F,
    6. Celentani D, et al.

    Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res 2020; 159: 104965.

    OpenUrlPubMedGoogle Scholar
26. 26.↵
    1. Tremblay D,
    2. van Gerwen M,
    3. Alsen M,
    4. Thibaud S,
    5. Kessler A,
    6. Venugopal S, et al.

    Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood 2020; 136: 144–147.

    OpenUrlCrossRefPubMedGoogle Scholar
27. 27.↵
    1. Kollias A,
    2. Kyriakoulis KG,
    3. Lagou S,
    4. Kontopantelis E,
    5. Stergiou GS,
    6. Syrigos K.

    Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med 2021; 26: 415–425.

    OpenUrlGoogle Scholar
28. 28.
    1. Hasan SS,
    2. Radford S,
    3. Kow CS,
    4. Zaidi STR.

    Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis 2020; 50: 814–821.

    OpenUrlCrossRefGoogle Scholar
29. 29.↵
    1. Tassiopoulos AK,
    2. Mofakham S,
    3. Rubano JA,
    4. Labropoulos N,
    5. Bannazadeh M,
    6. Drakos P, et al.

    D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 patients: A cohort study with a propensity-matched analysis. Front Med (Lausanne) 2021; 8: 631335.

    OpenUrlGoogle Scholar
30. 30.
    1. Paolisso P,
    2. Bergamaschi L,
    3. D’Angelo EC,
    4. Donati F,
    5. Giannella M,
    6. Tedeschi S, et al.

    Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol 2020; 11: 1124.

    OpenUrlCrossRefPubMedGoogle Scholar
31. 31.
    1. Lemos ACB

    , do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, Miranda CH. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359–366.

    OpenUrlCrossRefPubMedGoogle Scholar
32. 32.
    1. Helms J,
    2. Severac F,
    3. Merdji H,
    4. Schenck M,
    5. Clere-Jehl R,
    6. Baldacini M, et al.

    Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care 2021; 11: 14.

    OpenUrlPubMedGoogle Scholar
33. 33.
    1. Zhu W,
    2. Zhang H,
    3. Li Y,
    4. Ding Z,
    5. Liu Z,
    6. Ruan Y, et al.

    Optimizing management to reduce the mortality of COVID-19: experience from a designated hospital for severely and critically Ill patients in China. Front Med (Lausanne) 2021; 8: 582764.

    OpenUrlGoogle Scholar
34. 34.
    1. Yu B,
    2. Gutierrez VP,
    3. Carlos A,
    4. Hoge G,
    5. Pillai A,
    6. Kelly JD, et al.

    Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits. Biomark Res 2021; 9: 29.

    OpenUrlGoogle Scholar
35. 35.
    1. Poulakou G,
    2. Dimakakos E,
    3. Kollias A,
    4. Kyriakoulis KG,
    5. Rapti V,
    6. Trontzas I, et al.

    Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized COVID-19 patients: The ETHRA Study. In Vivo 2021; 35: 653–661.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
36. 36.
    1. Sadeghipour P,
    2. Talasaz AH,
    3. Rashidi F,
    4. Sharif-Kashani B,
    5. Beigmohammadi MT,
    6. Farrokhpour M, et al.

    Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA 2021; 325: 1620–1630.

    OpenUrlCrossRefPubMedGoogle Scholar
37. 37.
    1. Meizlish ML,
    2. Goshua G,
    3. Liu Y,
    4. Fine R,
    5. Amin K,
    6. Chang E, et al.

    Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol 2021; 96: 471–479.

    OpenUrlCrossRefPubMedGoogle Scholar
38. 38.
    1. Goligher EC,
    2. Bradbury CA,
    3. McVerry BJ,
    4. Lawler PR,
    5. Berger JS,
    6. Gong MN, et al.

    Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med 2021; 385: 777–789.

    OpenUrlCrossRefPubMedGoogle Scholar
39. 39.
    1. Atalla E,
    2. Zhang R,
    3. Shehadeh F,
    4. Mylona EK,
    5. Tsikala-Vafea M,
    6. Kalagara S, et al.

    Clinical presentation, course, and risk factors associated with mortality in a severe outbreak of COVID-19 in Rhode Island, USA, April-June 2020. Pathogens 2020; 10: 8.

    OpenUrlGoogle Scholar
40. 40.
    1. Rentsch CT,
    2. Beckman JA,
    3. Tomlinson L,
    4. Gellad WF,
    5. Alcorn C,
    6. Kidwai-Khan F, et al.

    Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ 2021; 372: n311.

    OpenUrlAbstract/FREE Full TextGoogle Scholar